Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemoradiotherapy vs chemoradiotherapy in locally recurrent nasopharyngeal carcinoma
ChiCTR2000035803Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of camrelizumab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: 2-year progression-free survival rate. Started Aug 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2000035803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035803.